Pharming Group NV 2021 AR2
The report outlines Pharming Group N.V.'s strategic and financial performance for the fiscal year 2021. During the year, the company focused on expanding the global reach of its lead product, RUCONEST, and preparing for the launch of leniolisib following positive Phase III clinical trial results. Pharming also entered a strategic collaboration with Orchard Therapeutics to develop OTL-105, a gene therapy for hereditary angioedema. To support its long-term sustainability, the company announced plans to establish an ESG committee and develop a structured ESG program in 2022.
Company: Pharming Group NV
Sector: Manufacturing
Country: Netherlands
Year: 2021
Type: AR2
Pages: 93
Back to company
Pharming Group NV
Annual Report
The report outlines Pharming Group N.V.'s strategic and financial performance for the fiscal year 2021. During the year, the company focused on expanding the global reach of its lead product, RUCONEST, and preparing for the launch of leniolisib following positive Phase III clinical trial results. Pharming also entered a strategic collaboration with Orchard Therapeutics to develop OTL-105, a gene therapy for hereditary angioedema. To support its long-term sustainability, the company announced plans to establish an ESG committee and develop a structured ESG program in 2022.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Employees